samedan logo
 
 
spacer
home > pmps > spring 2017 > is europe ready?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Is Europe Ready?

February saw an important milestone for all pharmaceutical manufacturers supplying the European market and their supply chain partners – the 9th marked the beginning of the two-year countdown until the EU’s Falsified Medicines Directive (EU-FMD) compliance mandate comes into force across Europe. From that date, pharma companies will no longer be able to legally put products on the European market unless they comply with the three critical ‘safety features’ requirements. Every pack of medicines must be:
  • Tamper-evidenced
  • Carrying a 2D data matrix encoding a unique identifier (UI)
  • The UI must have been uploaded into a Europe-wide system of repositories for systematic check-out at pharmacies
Achieving readiness to fulfil these conditions is a huge undertaking and the question being asked is: ‘How realistic is the prospect that Europe will be ready in February 2019?’ In order to answer this, let us consider the different areas of work in turn.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Christoph Krähenbühl, Senior Director at 3C Excellis Europe, is widely recognised as a thought leader in pharma serialisation. He has been involved in serialisation schemes since 2006 as Serialisation Project Manager and Product Security Manager at AstraZeneca. Christoph has also been supporting the European stakeholder response to the EU-FMD as an expert on the European Federation of Pharmaceutical Industries and Associations team and as a member of the EMVO management team.
spacer
Christoph Krähenbühl
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PerkinElmer Signals Research™ Suite Platform Integrates Scientific Data Silos and Enhances Collaboration for R&D Teams

WALTHAM, Mass. – October 25, 2021– PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of its Signals Research™ Suite, a full cloud based solution, deployed on Amazon Web Services. 
More info >>

White Papers

Advantages of Quantitative NMR for the Determination of Relative Response Factors

Novatia, LLC

Quantitative NMR (qNMR) is a technique that is being applied broadly and at an increasing rate in the field of pharmaceutical analysis (1). This white paper highlights the advantages of using qNMR to determine Relative Response Factors (RRFs) for pharmaceutical impurities detectable by HPLC. A single determination of RRFs using qNMR allows for simple and accurate quantitation of impurities which eliminates the need for preparation, qualification, and storage of reference standards. An example is presented here, which demonstrates quantitation of known impurities that have variable responses to UV-VIS detection, thereby providing a more accurate assessment of impurity levels than UV-VIS response alone.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement